You are here

P&T News

September 29

More than 3,000 cases reported in continental U.S.
Lumacaftor/ivacaftor combination previously approved for patients 12 years of age and older
“Artificial pancreas” adjusts insulin levels
Treatment reduces monthly migraine days

September 28

Singleplex trumps Trioplex, lab chief says
Arm patch provides continuous glucose monitoring
Compound could be used in new anti-inflammatory agents
Approval decision scheduled for July
First stakeholder meeting to be held this month

September 27

Regimen will target five tumor types and have seven indications
Endocrine Society publishes guideline evaluating technologies for treating diabetes
Combination did not improve progression-free survival for newly diagnosed patients
NIH-funded study seeks to explain the group’s disproportionate risk of the disease
Study includes nations that differ in economic development, income, and culture

September 26

Medication is indicated for the treatment of seven inflammatory diseases
It is the first biologic that targets interleukin-12 and interleukin-23 cytokines active in the disease
The potential blockbuster was granted breakthrough therapy status in 2014
Drug previously approved for cryopyrin-associated periodic syndromes and active systemic juvenile idiopathic arthritis
Studies also will address HIV prevention among at-risk groups

Pages